Author

Ania Mikolajczak

The Francis Crick Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Alicia Alonso de la VegaiD· 1 shared Andrea de CastroiD· 1 shared Christopher Moore· 1 shared Claire E. PillsburyiD· 1 shared James CampbelliD· 1 shared Julian DownwardiD· 1 shared KangBo NgiD· 1 shared Míriam Molina‐ArcasiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alicia Alonso de la VegaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumor cells

Mona Tomaschko, KangBo Ng, Christopher Moore, Claire E. Pillsbury, Sareena Rana, James Campbell, Saptaparna Mukherjee, Ania Mikolajczak, Panayiotis Anastasiou, Andrea de Castro, Alicia Alonso de la Vega, Sophie de Carné Trécesson, Nathan W. Goehring, Míriam Molina‐Arcas, Julian Downward

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

bioRxiv · Oct 27, 2025 · PreprintCancer Biology